US Stock Market Movement: Precigen surged on September 30th due to FDA platform approval and Papzimeos volume increase

Precigen September 30 Surge Interpretation

Keywords: FDA platform certification, Papzimeos volume increase

1. On September 21, 2026, the FDA granted platform technology certification to Precigen’s AdenoVerse immunotherapy platform. This platform has already supported the approved drug Papzimeos. The related certification creates conditions for future drug applications to reuse part of the manufacturing and preclinical knowledge.

2. Disclosed on September 30, 2026: Papzimeos achieved $74.6 million in revenue in the first six months of 2026, with product revenue in Q2 2026 more than doubling quarter-on-quarter.

3. Disclosed on September 30, 2026: Papzimeos is currently the first and only FDA-approved therapy for adult recurrent respiratory papillomatosis. Its European marketing authorization application is under review, and it enjoys an FDA market exclusivity period until August 14, 2032.

(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)